A STUDY ON THE ADVANCEMENT OF COCAINE HYDROLASE FOR THERAPEUTIC INTERVENTION IN COCAINE-RELATED VIOLENCE

Shi Yanhua[1], Farra Aidah Jumuddin[2]

ABSTRACT

Lack of effective pharmaceutical therapies for cocaine addiction is a serious matter, posing a public health emergency. The goal of this research was to create a synthetic enzyme called cocaine hydrolase (CocH) that would lessen the cognitive and physiological harm that cocaine causes. Cocaine would be broken down into inert byproducts very quickly by this enzyme. In this study, the researcher investigate the possibility of structurally optimizing CocH to increase its selectivity, stability, and catalytic activity while decreasing its off-target effects. Research in this area primarily aims to build enzymes via protein design, characterize CocH variations in vivo and in vitro, and evaluate their therapeutic potential in preclinical studies. The results show that improved CocH reduces drug-induced behavioral reactivity and increases cocaine metabolism in animal models. To guarantee that CocH is appropriate for clinical use, the research also explores possible immunogenicity, safety, and delivery methods. This study adds to the growing body of evidence supporting enzyme-based therapy as a promising new avenue for the treatment of cocaine addiction. Cocaine addiction is a rising public health concern because to the destructive effects it has on people's mental health, relationships, and capacity to make ends meet. There has been a lot of study on cocaine dependency, but pharmaceutical treatments have not proved effective. An designed enzyme called cocaine hydrolase (CocH) is the primary focus of this research because of its ability to quickly degrade cocaine into benzoic acid and ecgonine methyl ester, two non-pharmacological byproducts, at a pace that is far greater than the body's normal metabolism.

Keywords: *Enzyme Security, Directed the Theory Of Evolution, Pharmacokinetics, Cocaine Toxicity.*

1. INTRODUCTION

Our primary objective is to develop a gene-transfer delivery method capable of producing large quantities of an effective hydrolase in a safe manner. Addicts in recovery will find this helpful in avoiding relapse. The effects of cocaine on the brain's reward regions are either entirely or greatly diminished by this enzyme. A crucial enzyme in the proper metabolism of cocaine is butyrylcholinesterase (BChE). The idea and subsequent discovery of an Fc-fused hCocH dimer (hCocH-Fc) occurred during the development of the long-acting hCocHs. Its counterpart is the catalytic antibody. The biological half-life of hCocH-Fc is much longer, and it also demonstrates considerable catalytic activity against cocaine. Twenty days after injection, a single dosage of hCocH-Fc prevented cocaine-induced hyperactivity in rats and accelerated cocaine metabolism. The hCocH-Fc may enable dosage every two to four weeks, or even longer, for the treatment of cocaine addiction in humans, since the biological half-life of a protein medication is much longer in humans compared to rats (Gill et al.,2023). By preventing blood cocaine levels from rising over the minimal effective concentration, pharmacokinetic agents primarily seek to alleviate cocaine addiction (21). The ideal treatment for cocaine addiction would be enzymes that have a long half-life in living organisms and significant catalytic efficiency against cocaine. The production of physiologically inactive metabolites occurs during the hydrolysis of cocaine by many metabolic enzymes, one of which is BChE. Regrettably, the naturally occurring (-)-cocaine cannot be enhanced by the wild-type BChE enzyme due to its insufficiently high catalytic efficiency (kcat/KM) (kcat = 4.1 min−1 and KM = 4.5 μM). The research presented here primarily aimed to formulate this strategy for the creation of potential CocHs to treat cocaine addiction. Along with Fc(M3), the A1V/D142E/L144M mutant (33) of Fc, our recently identified cocH3 protein also has

an IL-2 signal peptide attached to its N-terminus. In order to further reduce the likelihood of steric interference between Fc(M3) and CocH3, the tetramerization region (amino acid residues from #530 to #574) of CocH3 was subsequently removed. Links (L) between the Fc(M3) and CocH3 domains were carefully considered after much deliberation. For the purpose of optimizing the PK profile, the researcher produced and tested a number of Fc(M3)-L-CocH3 entities against cocaine and their pharmacokinetic profiles in rats. Most encouraging, according to the results, was Fc(M3) fusion at the N-terminus of CocH3 (Nakazawa et al., 2019).

2. BACKGROUND OF THE STUDY

Cocaine addiction affects not only the addict but also their loved ones and the society as a whole. The euphoric effects and strong addictive potential of cocaine are caused by its capacity to impede dopamine reuptake in the brain. An effective therapy is urgently needed since long-term usage has the potential to cause brain abnormalities, cardiovascular difficulties, and social dysfunction. No pharmaceutical therapies for cocaine dependency have been authorized by the FDA as of yet, regardless of the circumstances. The need for innovative and focused therapeutic methods is pressing since, despite their usefulness, behavioral therapies may produce varying degrees of success (Cenci et al., 2022). Cocaine hydrolase (CocH), an engineered enzyme mimicking human butyrylcholinesterase (BChE), may help reduce cocaine addiction. Although BChE breaks down cocaine into inert metabolites, its sluggish metabolism means it can't delay the onset of effects. Advances in protein engineering have made it possible to create CocH variations that are more efficient catalysts. This aids in the breakdown of cocaine. When used to treat or prevent cocaine overdose, COCH either eliminates or significantly reduces the euphoric effects of the drug. The

goal of this research is to fill in some major blanks in CocH by investigating its biochemical characteristics, finding strategies to improve its function via protein engineering, and testing how well it works as a therapy in animal models. Insight into enzyme-based treatments for cocaine usage and the creation of a new, effective medicine to address this widespread problem are the overarching goals of this study. Research on the effectiveness, safety, and administration methods of CocH will be covered (Connery et al., 2020).

3. PURPOSE OF THE STUDY

The fundamental objective of this research is to understand how to best use cocaine hydrolase (CocH) as a novel therapeutic agent to treat cocaine addiction and misuse. A novel enzyme called cocaine hydrolase quickly degrades cocaine into harmless byproducts, minimizing the drug's harmful and euphoric effects. This work intends to generate an enzyme that may significantly speed the elimination of cocaine from the blood by improving the catalytic efficiency of CocH via the application of sophisticated protein engineering. Evaluating the therapeutic potential of CocH in mitigating the physiological and behavioral impacts of cocaine is another primary objective. The researcher will test it out in preclinical animals to see whether it may lessen the rewarding effects of cocaine, which might mean it's a great alternative for therapy. The safety of CocH for clinical usage is ensured by studying its immunogenicity, stability, and off-target effects. The research delves into other methods of giving CocH, including gene therapy and direct protein injection, to produce effective and long-lasting therapeutic benefits. This study aims to alleviate the suffering of those impacted by drug misuse and acute cocaine toxicity by developing a new

enzyme-based therapy that outperforms existing pharmaceutical therapies for cocaine addiction. The researcher are striving to find a therapy that is safe for patients without compromising efficacy so that the researcher may swiftly lower the social and public health costs of cocaine addiction.

4. LITERATURE REVIEW

Substance abuse, and especially cocaine addiction, affects not just the addict but also their loved ones and the larger community. Behavioral treatments such as contingency management and cognitive behavioral therapy (CBT) have a long history of use in the treatment of cocaine addiction. Additional pharmaceutical treatments are required when these medications fail to alleviate symptoms due to high recurrence rates (Martell et al., 2023). The FDA has not approved any drugs for the treatment of cocaine addiction, hence there is an extreme lack of options for those struggling with this addiction. This has been the case for hundreds of years of study. Treatment based on enzymes, which simulate the metabolic pathways via which drugs are eliminated from the body, is one approach that shows promise. Despite its intriguing ability to breakdown cocaine into inactive forms, human butyrylcholinesterase (BChE) is therapeutically useless due to its fundamentally poor catalytic efficiency. Cocaine hydrolase (CocH), an improved version of BChE made possible by recent developments in protein engineering, is much more effective against cocaine. Researchers have shown that COCH can break down cocaine quickly, which means less of the drug in the blood and less of its hallucinatory effects. Results from animal models of cocaine overdose and behaviors produced by cocaine show promise in preclinical investigations of CocH. In addition, these findings imply that COCH may reduce cocaine's intoxicating effects, which may lead to less cravings and the elimination of the desire to relapse. Reducing the enzyme's

immunogenicity, stabilizing it in vivo, and improving its delivery are all necessary steps toward achieving long-term therapeutic benefits. Coenzyme H (CocH) expression using adeno-associated virus (AAV)-mediated delivery is an interesting gene therapy approach that may provide patients a new long-term therapeutic alternative. The need of addressing safety concerns is also emphasized in the literature (Vasiliu et al., 2021).

5. RESEARCH QUESTION

- What is the impact of permanent protection against relapse on Therapeutical Treatment of Cocaine Abuse Treatment?

6. RESEARCH METHODOLOGY

Quantitative research refers to studies that examine numerical readings of variables using one or more statistical models. The social environment may be better understood via quantitative research. Quantitative approaches are often used by academics to study problems that impact particular individuals. Objective data presented in a graphical format is a byproduct of quantitative research. Numbers are crucial to quantitative research and must be collected and analyzed in a systematic way. Averages, predictions, correlations, and extrapolating findings to larger groups are all possible with their help.

- **Research design:** Quantitative data analysis was conducted using SPSS version 25. The combination of the odds ratio and the 95% confidence interval provided information about the nature and trajectory of this statistical association. The p-value was set at less than 0.05

as the statistical significance level. The data was analyzed descriptively to provide a comprehensive understanding of its core characteristics. Quantitative approaches are characterized by their dependence on computing tools for data processing and their use of mathematical, arithmetic, or statistical analyses to objectively assess replies to surveys, polls, or questionnaires.

- **Sampling:** After pilot research with 20 Chinese Researcher, 1100 Rao-soft pupils were included in the final Investors. Male and female Researcher were picked at random and then given a total of 1,455 surveys to fill out. A total of 1253 questionnaires were used for the calculation after 1300 were received and 47 were rejected due to incompleteness.
- **Data and Measurement:** A questionnaire survey served as the main data collector for the study. There were two sections to the survey: (A) General demographic information and (B) Online & non-online channel factor replies on a 5-point Likert scale. Secondary data was gathered from a variety of sources, with an emphasis on online databases.
- **Statistical Tools:** Descriptive anaAlysis was used to grasp the fundamental character of the data. The researcher applied ANOVA for the analysis of the data.

7. CONCEPTUAL FRAMEWORK



8. RESULT

❖ Factor analysis

One typical use of Factor Analysis (FA) is to verify the existence of latent components in observable data. When there are not easily observable visual or diagnostic markers, it is common practice to utilize regression coefficients to produce ratings. In FA, models are essential for success. Finding mistakes, intrusions, and obvious connections are the aims of modelling. One way to assess datasets produced by multiple regression studies is with the use of the Kaiser-Meyer-Olkin (KMO) Test. They verify that the model and sample variables are representative. According to the numbers, there is data duplication. When the proportions are less, the data is easier to understand. For KMO, the output is a number between zero and one. If the KMO value is between

0.8 and 1, then the sample size should be enough. These are the permissible boundaries, according to Kaiser: The following are the acceptance criteria set by Kaiser:

A dismal 0.050 to 0.059, subpar 0.60 to 0.69

Middle grades often range from 0.70 to 0.79.

Exhibiting a quality point score between 0.80 and 0.89.

They are astonished by the range of 0.90 to 1.00.

Table 1: KMO and Bartlett's Test for Sampling Adequacy Kaiser-Meyer-Olkin measurement: .993

The outcomes of Bartlett's test of sphericity are as follows: Approximately chi-square degrees of freedom = 190 significance = 0.000

This confirms the legitimacy of claims made just for sampling purposes. Researchers used Bartlett's Test of Sphericity to ascertain the significance of the correlation matrices. A Kaiser-Meyer-Olkin value of 0.993 indicates that the sample is sufficient. The p-value is 0.00 according to Bartlett's sphericity test. A positive outcome from Bartlett's sphericity test indicates that the correlation matrix is not an identity matrix.

Table: KMO and Bartlett's

KMO and Bartlett's Test		
Kaiser-Meyer-Olkin Measure of Sampling Adequacy.		.993
Bartlett's Test of Sphericity	Approx. Chi-Square	3252.968
	df	190
	Sig.	.000

The overall significance of the correlation matrices was further confirmed by using Bartlett's Test of Sphericity. A value of 0.993 was the Kaiser-Meyer-Olkin sampling adequacy. By using Bartlett's sphericity test, researchers found a p-value of 0.00. A significant test result from Bartlett's sphericity test demonstrated that the correlation matrix was not a correlation matrix.

❖ INDEPENDENT VARIABLE

➢ The Development of Cocaine Hydrolase

A genetically modified enzyme called cocaine hydrolase (CocH) may quickly degrade cocaine into inert byproducts like benzoic acid and ecgonine methyl ester. The selectivity and catalytic efficacy of CocH are greatly improved by modifications as it is derived from or based on human butyrylcholinesterase (BChE). By increasing the blood metabolic rate, CocH aims to lessen the harmful and intoxicating effects of cocaine. For this reason, it shows potential as a medicinal therapy for cocaine addiction, overdose, and associated symptoms. The fact that COCH reduces the euphoric and reinforcing effects of cocaine by blocking its brain connections provides support for methods of managing both short-term and long-term addictions to the substance (López-Pelayo et al., 2020).

❖ FACTOR

➢ Permanent Protection Against Relapse

When a person is able to maintain their resistance to relapsing after experiencing a period of improvement or remission, the researcher says that they have achieved permanent protection against relapse. The idea that a person may remain sober forever, even when faced with the same stresses, triggers, or high-risk scenarios that caused them to relapse in the past is central to the field of mental health, addiction, and chronic illness treatment (Onyeka et al., 2019).

❖ DEPENDENT VARIABLE

➢ Therapeutical Treatment of Cocaine Abuse Treatment

A broad variety of medical and psychological treatments are used in therapeutic therapies with the goal of reducing, controlling, or curing a particular medical or psychiatric illness. Health improvement, normal functioning restoration, and symptom reduction are the goals of these individualized therapies. Medication is one kind of pharmacological treatment; physical therapy includes exercises and rehabilitation; counseling and cognitive-behavioral therapy are forms of psychological therapy; and acupuncture and massage are complementary therapies. In addition to reducing symptoms, therapeutic therapy aims to improve the patient's health in the long run, stop the disease from coming back, and raise their standard of living. It is common practice to collect comprehensive information on each patient's health background, symptoms, and illness severity to tailor treatment plans. It may be useful for acute disease treatment, long-term health condition management, and rehabilitation after injuries or surgeries (Vasiliu, 2019).

- **Relationship between Permanent Protection Against Relapse and Therapeutical Treatment of Cocaine Abuse Treatment**

Because therapeutic interventions are essential in attaining and sustaining a relapse-resistant state, permanent protection against relapse and therapeutic treatment are intimately related. When it comes to addiction, mental health issues, and chronic diseases, where recurrence is often a major obstacle, this connection becomes even more important. Methadone for opioid addiction and mood stabilizers for mental health issues are examples of maintenance therapy that are crucial in giving continuous assistance to maintain recovery. Anxiety, sadness, or trauma are all examples of co-occurring illnesses that might make relapse more likely; treating these disorders simultaneously is generally necessary for successful treatment. Reinforcing rehabilitation and ensuring continual development, long-term care includes occasional therapy sessions, support groups, and medication modifications. New methods are improving results even more by adapting treatments to each patient's unique requirements; examples include neurofeedback and individualized treatment programs. Individuals have a higher chance of achieving long-term recovery and wellness by integrating various therapy approaches, which together provide lasting protection against recurrence (Kitching et al., 2020).

Based on the above discussion, the researcher formulated the following hypothesis, which was to analyze the relationship between Permanent Protection Against Relapse and Therapeutical Treatment of Cocaine Abuse Treatment .

H_{01}: "There is no significant relationship between Permanent Protection Against Relapse and Therapeutical Treatment of Cocaine Abuse Treatment"

H_1: "There is a significant relationship between Permanent Protection Against Relapse and Therapeutical Treatment of Cocaine Abuse Treatment"

Table 2: H_1 ANOVA Test

ANOVA					
Sum					
	Sum of Squares	**df**	**Mean Square**	**F**	**Sig.**
Between Groups	39588.620	590	5655.517	563.695	.000
Within Groups	492.770	662	5.356		
Total	40081.390	1252			

This investigation yields remarkable results. The F value is 563.695, achieving significance with a p-value of .000, which is below the .05 alpha threshold. This means ***"H_1: There is a significant relationship between Permanent Protection Against Relapse and Therapeutical Treatment of Cocaine Abuse Treatment"*** The alternative hypothesis is accepted, whereas the null hypothesis is rejected.

9. CONCLUSION

There have been significant advancements in the treatment of cocaine usage and addiction with the use of cocaine hydrolase (CocH). Reducing the intoxicating effects and toxicity risk of cocaine, CocH has shown the capacity to quickly convert the substance into inactive metabolites via optimization and genetic engineering. By combining this novel enzyme-based therapy with behavioral therapies and more conventional pharmaceutical techniques, it may be possible to overcome the drawbacks of current methods. Animal preclinical investigations have shown that CocH successfully decreases cocaine-induced behaviors and prevents overdose, suggesting its potential usefulness as a therapy and preventative measure. Research into other routes of delivery,

such gene therapy and recombinant protein injection, shows that CocH may be modified to provide therapeutic benefits with longer half-lives. Although there are still many obstacles to overcome, such as ensuring safety in clinical settings, reducing immunogenicity, and improving enzyme stability, progress has been encouraging. Anyone trying to create enzyme-based treatments for preventing drug overdoses and cocaine addiction should give serious thought to the study's conclusions. If COCH undergoes more testing in humans, it has the potential to provide a novel and efficient approach to treating cocaine, therefore addressing a widespread issue in public health. By bringing together state-of-the-art biotechnology with time-tested therapeutic methods, this study lays the groundwork for a more all-encompassing strategy for addiction treatment. Dartevel et al say those fighting cocaine addiction may so anticipate better results (Dartevel et al., 2019).

REFERENCE

Nakazawa, D.; Masuda, S.; Tomaru, U.; Ishizu, A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat. Rev. Rheumatol. 2019, 15, 91–101.

Connery HS, McHugh RK, Reilly M, Shin S, Greenfield SF. Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments. Harv Rev Psychiatry. (2020) 28:316–27.

Vasiliu O, Vasile D, Vasiliu DG, Ciobanu OM. Quality of life impairments and stress coping strategies during the Covid-19 pandemic isolation and quarantine- A web-based survey. Rom J Mil Med. (2021) 124:10–21.

López-Pelayo H, Aubin HJ, Drummond C, Dom G, Pascual F, Rehm J, et al. "The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic. BMC Med. (2020) 18:241.

Onyeka IN, Høegh MC, Eien EMN, Nwaru BI, Melle I. Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: a systematic review and meta-analysis. J Dual Diagn. (2019) 15:192–206.

Vasiliu O. Maintenance pharmacologic therapies for opioid use disorders: beyond opioid agonists. Rom J Mil Med. (2019) CXXII:52–70.

Kitching, A.R.; Anders, H.J.; Basu, N.; Brouwer, E.; Gordon, J.; Jayne, D.R.; Kullman, J.; Lyons, P.A.; Merkel, P.A.; Savage, C.O.S.; et al. ANCA-associated vasculitis. Nat. Rev. Dis. Primers 2020, 6, 71.

Dartevel, A.; Chaigne, B.; Moachon, L.; Grenier, F.; Dupin, N.; Guillevin, L.; Bouillet, L.; Mouthon, L. Levamisole-induced vasculopathy: A systematic review. Semin. Arthritis Rheum. 2019, 48, 921–926.

Gill, C.; Sturman, J.; Ozbek, L.; Henderson, S.R.; Burns, A.; Hamour, S.; Pepper, R.J.; McClelland, L.; Chanouzas, D.; Gane, S.; et al. Cocaine-induced granulomatosis with polyangiitis-an under-recognized condition. Rheumatol. Adv. Pr. 2023, 7, rkad027.

Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. (2020) 66:1116–23.